AgomAb Therapeutics (AGMB)
Develops organ-restricted ALK5 inhibitors for fibro-inflammatory diseases.
Something off on this page? Send us feedback.
Develops investigational, organ-restricted therapies for fibro-inflammatory disease. Its pipeline includes oral ontunisertib and inhaled AGMB-447, while clinical development and regulatory progress determine its path to commercialization.
Develops investigational therapies for fibro-inflammatory disease, combining earlier HGF-mimetic antibody research with a platform centered on organ-restricted ALK5 inhibition. Ontunisertib, also called AGMB-129, is an oral GI-restricted candidate; AGMB-447 is an inhaled lung-restricted candidate. AGMB-101 is ready for initial clinical testing.
Operations span Belgium, Spain and the United States through the parent company and two wholly owned subsidiaries. The portfolio was expanded through the acquisition of Origo Biopharma, where the two ALK5 candidates were discovered. Its public-company profile is built around research, candidate discovery or acquisition, intellectual property and clinical development rather than marketed products. Progress depends on clinical development and regulatory advancement of investigational candidates.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $292.6M · Total debt $1.3M · Total assets $337.9M · Shareholders' equity $308.2M
- Revenue
- $0
- Operating income
- −$19.2M
- Net income
- −$20.2M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions32 holders · as of Mar 31, 2026 | 47.42% | 23.35M shares | |
| Otherremainder | 52.58% | 25.89M shares |
49.25M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Eqt Fund Management S.A R.L.Institution | 10.44% | 5.14M | 13Fas of Mar 31, 2026 |
SanofiInstitution | 5.65% | 2.78M | 13Fas of Mar 31, 2026 |
Cormorant Asset Management, LPInstitution | 5.01% | 2.47M | 13Fas of Mar 31, 2026 |
TCG Crossover Management, LLCInstitution | 4.17% | 2.05M | 13Fas of Mar 31, 2026 |
Federated Hermes, Inc.Institution | 3.29% | 1.62M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- AbbVie
Approved Crohn's disease therapies Rinvoq and Skyrizi
- Johnson & Johnson
Approved Crohn's disease therapy Tremfya
- Takeda (ADR)
Gut-selective Crohn's disease therapy Entyvio
- Eli Lilly
Approved Crohn's disease therapy Omvoh
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AgomAb Therapeutics | $13.60 | +0.44% | $672.7M | — | — | — | — |
| AbbVie | $261.72 | +0.00% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Johnson & Johnson | $275.70 | +0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Takeda (ADR) | $18.53 | +0.47% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Eli Lilly | $1,165.04 | +0.49% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Median | 45.1 | 25.7 | 7.0 | +8.4% |